DDX11 and nonpapillary renal cell carcinoma: To overcome these limitations and validate our findings, a prospective clinical trial is now underway (ClinicalTrials.gov Identifier: NCT03694912) that will include an examination of the mutation profiles of the selected genes (PBRM1, BAP1, SETD2, KDM5C, FOXC2, CLIP4, MOCOS, BAIAP2L1, DDX11, and AQP1) for aggressive ccRCC.